Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder.
For Sample copy of this Report: https://www.researchnreports.com/request_sample.php?id=81085
Epilepsy is a group of neurological diseases characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable to long periods of vigorous shaking. These episodes can result in physical injuries including occasionally broken bones. The medical definition of this disease is as a “condition characterized by recurrent (two or more) epileptic seizures, unprovoked by any immediate identified cause”. Epilepsy is divided into four main types; idiopathic generalized epilepsy, idiopathic partial epilepsy, symptomatic generalized epilepsy and symptomatic partial epilepsy. The cause of epilepsy can be genetic, a result of other disorders such as tumor or brain injury and due to certain seizure triggers.
For More information / Ask you’re Quires: http://bit.ly/2qUbFmt
Epilepsy is treated via antiepileptic drugs, surgery in certain cases and several complementary therapies such as ketogenic diets or neural stimulation. Based upon the drug type, epilepsy market can be divided into three main categories; first generation drugs, second generation drugs and third generation drugs.
The global epilepsy market is driven by factors such as development of novel drugs, launch of new drugs in developing regions and prevalence of neural disorders such as meningitis and tumors. This growth is then further spearheaded by increasing healthcare expenses and rising disposable incomes. However, the market growth is hindered by tedious drug approval process, generic erosion and high cost of treatment. Trends such as companies focusing on developing effective therapies for refractory epilepsy and physicians demanding higher efficacy drugs are listed in this report. various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.
The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period
North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities
Some major players of the epilepsy drugs market include UCB Pharma Ltd., Sanofi S.A, Valeant Pharmaceuticals International, Inc., Pfizer, Inc., Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC., Sunovion Pharmaceuticals, Inc., and Cephalon, Inc.
The report analysis Market driver, Growing number of fractionating units, Market challenges, Complex and cost-intensive manufacturing, Market trend, Monetary support, Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Get Discount on This Premium Research now at: https://www.researchnreports.com/ask_for_discount.php?id=81085